Tag Archives: ADC technology

August, 2018

2 August
Daiichi Sankyo Enters Worldwide Licensing Agreement with Glycotope for Gatipotuzumab Antibody Drug Conjugate

Tokyo, Berlin, Basking Ridge, NJ – (July 30, 2018) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and Glycotope GmbH (hereafter, Glycotope) have entered into an exclusive worldwide licensing agreement to develop an antibody drug conjugate (ADC) by combining Daiichi Sankyo’s proprietary ADC technology with Glycotope’s investigational tumor-associated TA-MUC1 antibody gatipotuzumab …
Share

30 October
Daiichi Sankyo & Glycotope Enter Option Agreement for Antibody Drug Conjugate Strategic Collaboration and Licensing

TOKYO and BASKING RIDGE, N.J., and BERLIN, Oct. 30, 2017 /PRNewswire/ — Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and Glycotope GmbH (hereafter, Glycotope) have signed an option agreement for future strategic collaboration and licensing to develop an antibody drug conjugate (ADC) by combining Daiichi Sankyo’s proprietary ADC technology with …
Share

11 November
Pulse Biosciences’ NPS Technology Demonstrates Positive Results in Immuno-Oncology Studies

BURLINGAME, Calif.–(BUSINESS WIRE)–Pulse Biosciences, Inc., (NASDAQ:PLSE), a medical technology company developing a proprietary therapeutic treatment platform based on Nano-Pulse Stimulation (NPS), today announced the results of three preclinical studies that further validate the NPS technology and its potential role in novel immunotherapeutic approaches. The new data, which will be presented …
Share

16 April
Sanofi and Innate Pharma Collaborate to Develop Next Generation ADCs

Sanofi is teaming up with Innate Pharma to use its technology for development of new antibody drug conjugates (ADC). Today, France’s Innate Pharma announced that it has entered into a collaboration agreement to apply Innate’s site-specific conjugation technology to the development of new ADC. The companies did not disclose financial …
Share

23 March
ImmunoGen Licenses ADC Technology to Takeda for Development of Cancer Drugs

Oncology biotech ImmunoGen, Inc. announced that it has entered into a $440 million antibody-drug conjugate (ADC) licensing deal with Takeda Pharmaceutical Company Limited. Takeda has licensed exclusive rights to use ImmunoGen’s ADC technology to develop and commercialize targeted anticancer therapeutics to up to two undisclosed targets. Under the deal, ImmunoGen …
Share